VUMERITY Drug Patent Profile

Which patents cover Vumerity, and when can generic versions of Vumerity launch?

Vumerity is a drug marketed by Biogen and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in VUMERITY is diroximel fumarate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the diroximel fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vumerity

A generic version of VUMERITY was approved as diroximel fumarate by ZYDUS on November 12^th, 2025.

Summary for VUMERITY

US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	48
Clinical Trials:	4
Patent Applications:	275
Drug Prices:	Drug price information for VUMERITY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VUMERITY
What excipients (inactive ingredients) are in VUMERITY?	VUMERITY excipients list
DailyMed Link:	VUMERITY at DailyMed

See drug prices for VUMERITY

Recent Clinical Trials for VUMERITY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Nebraska	EARLY_PHASE1
Biogen	Phase 1
Biogen	Phase 3

See all VUMERITY clinical trials

Paragraph IV (Patent) Challenges for VUMERITY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VUMERITY	Delayed-release Capsules	diroximel fumarate	231 mg	211855	1	2020-12-23

US Patents and Regulatory Information for VUMERITY

VUMERITY is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biogen	VUMERITY	diroximel fumarate	CAPSULE, DELAYED RELEASE;ORAL	211855-001	Oct 29, 2019	AB	RX	Yes	Yes
Biogen	VUMERITY	diroximel fumarate	CAPSULE, DELAYED RELEASE;ORAL	211855-001	Oct 29, 2019	AB	RX	Yes	Yes			Y	Y
Biogen	VUMERITY	diroximel fumarate	CAPSULE, DELAYED RELEASE;ORAL	211855-001	Oct 29, 2019	AB	RX	Yes	Yes			Y	Y

EU/EMA Drug Approvals for VUMERITY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Biogen Netherlands B.V.	Vumerity	diroximel fumarate	EMEA/H/C/005437Vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see Section 5.1 for important information on the populations for which efficacy has been established).	Authorised	no	no	no	2021-11-15

International Patents for VUMERITY

When does loss-of-exclusivity occur for VUMERITY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Netherlands

New Zealand

Norway

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VUMERITY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014239641
Australia	2016222363
Australia	2018200497
Brazil	112015022854

Supplementary Protection Certificates for VUMERITY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2970101	301165	Netherlands		PRODUCT NAME: DIROXIMELFUMARAAT; REGISTRATION NO/DATE: 68066 20210920
2970101	PA2022003	Lithuania		PRODUCT NAME: DIROKSIMELIO FUMARATAS ; REGISTRATION NO/DATE: EU/1/21/1585 20211115
2970101	2022C/507	Belgium		PRODUCT NAME: DIROXIMEL FUMARATE; AUTHORISATION NUMBER AND DATE: EU/1/21/1585 20211116
2970101	LUC00251	Luxembourg		PRODUCT NAME: DIROXIMEL FUMARATE; AUTHORISATION NUMBER AND DATE: 68066; 20210920

Last updated: August 12, 2026

Vumerity has become a meaningful growth product for Biogen, but its commercial opportunity is tied to conversion from Tecfidera rather than expansion of the multiple-sclerosis market. Diroximel fumarate benefits from Biogen’s established fumarate franchise, twice-daily oral dosing, and a gastrointestinal tolerability profile designed to improve on dimethyl fumarate. Its principal risks are generic erosion of Tecfidera, payer pressure, competition from high-efficacy MS therapies, and eventual patent challenges against Vumerity’s formulation and method-of-use protection.

Vumerity Market Dynamics, Revenue Trajectory, Patents, and Generic Risk

What is Vumerity and how does it compete in multiple sclerosis?

Vumerity is the brand name for diroximel fumarate, an oral fumarate therapy for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. Biogen markets Vumerity in the United States and other jurisdictions.

The drug is a prodrug that is rapidly converted to monomethyl fumarate, the same pharmacologically active metabolite generated by Tecfidera, or dimethyl fumarate. Biogen positioned Vumerity as a next-generation fumarate with improved gastrointestinal tolerability.

The product competes across three treatment segments:

Segment	Main competitors	Vumerity’s commercial position
Oral fumarates	Tecfidera, generic dimethyl fumarate, Bafiertam	Differentiated by formulation and tolerability
Oral disease-modifying therapies	Aubagio, generic teriflunomide, Gilenya generics, Mayzent, Zeposia	Competes on convenience and familiarity
High-efficacy therapies	Tysabri, Ocrevus, Kesimpta, Lemtrada	Generally stronger efficacy perception but higher monitoring, safety, or administration burden

Vumerity does not compete primarily as a superior-efficacy product. Its commercial proposition is a balance of oral convenience, established fumarate biology, and reduced gastrointestinal burden relative to Tecfidera.

How has Vumerity revenue developed since launch?

Vumerity launched in the United States in 2020 after FDA approval on Oct. 30, 2019. Revenue expanded rapidly as Biogen shifted patients from Tecfidera and as prescribers sought an alternative for patients experiencing gastrointestinal adverse events.

Biogen’s reported product revenue increased from a small launch base to several hundred million dollars annually:

Period	Vumerity revenue trend	Primary driver
2020	Initial commercial contribution	U.S. launch and early adoption
2021	Approximately $150 million	Conversion from Tecfidera and broader formulary access
2022	Approximately $260 million to $300 million	Continued switching and commercial execution
2023	Approximately $400 million or more	Mature U.S. uptake and international expansion
2024 onward	Continued growth, subject to market access and competition	Franchise migration and new-patient prescribing

The exact reported amount varies by annual-report presentation and foreign-exchange treatment. Biogen’s annual filings show a strong upward trajectory through 2023, while Tecfidera revenue declined after generic entry.[1-3]

Vumerity’s growth has partly offset the loss of Tecfidera revenue. That substitution is strategically important because Tecfidera was once one of Biogen’s largest products, generating several billion dollars in annual sales before generic competition intensified.

What is driving Vumerity’s market growth?

Conversion from Tecfidera

The largest source of Vumerity growth is switching within Biogen’s own fumarate franchise. Tecfidera established the clinical and commercial market for oral fumarate treatment. Vumerity gives Biogen a branded alternative for patients who might otherwise discontinue Tecfidera, switch to another oral therapy, or move to an injectable or infusion product.

This internal migration limits the net loss to Biogen when Tecfidera prescriptions move to generic dimethyl fumarate.

Gastrointestinal tolerability

Vumerity was developed to produce fewer gastrointestinal events than Tecfidera in controlled clinical studies. In the EVOLVE-MS-2 trial, Vumerity produced a lower burden of gastrointestinal adverse events than delayed-release dimethyl fumarate.[4]

This benefit is commercially relevant because gastrointestinal symptoms can affect adherence, persistence, and patient satisfaction. The advantage is strongest among patients who are clinically stable on a fumarate but cannot tolerate Tecfidera.

Vumerity is not free of gastrointestinal risk. Nausea, diarrhea, abdominal pain, flushing, lymphopenia, and liver-related laboratory abnormalities remain relevant safety considerations. Its tolerability advantage therefore supports switching, but it does not eliminate monitoring or discontinuation risk.

Oral administration

Vumerity is administered orally twice daily. Oral dosing remains attractive in MS because it avoids injections and infusion-center visits. The advantage is narrower than it was when Tecfidera launched because the market now includes several oral and self-administered therapies.

Biogen’s commercial infrastructure

Biogen has established relationships with neurologists, specialty pharmacies, payers, and MS patient-support programs. Vumerity benefits from this infrastructure and from the company’s large installed base of Tecfidera users.

How does Vumerity compare with Tecfidera and generic dimethyl fumarate?

Vumerity and Tecfidera generate the same active metabolite, but they are not interchangeable at the product level. Vumerity’s value proposition depends on the formulation and the clinical consequences of that formulation.

Factor	Vumerity	Tecfidera	Generic dimethyl fumarate
Active therapeutic pathway	Monomethyl fumarate exposure through prodrug conversion	Monomethyl fumarate exposure through dimethyl fumarate conversion	Same active pathway as Tecfidera
Dosing	Twice daily	Twice daily	Usually equivalent to reference-product regimen
Main differentiation	GI tolerability and branded support	Established clinical history	Lower price
Payer position	Often requires preferred-brand justification	Increasingly disadvantaged by generics	Preferred on cost
Commercial risk	Price competition and branded erosion	Generic substitution	Formulary and reimbursement dependence

Vumerity’s economic defense is strongest where the payer or prescriber accepts a premium for tolerability and persistence. It is weakest in plans that require generic dimethyl fumarate before approving Vumerity.

What is the FDA regulatory status of Vumerity?

Vumerity was approved by the FDA in 2019 under NDA 211855 for relapsing forms of MS.[5] It is a small-molecule prescription drug, not a biologic.

The regulatory framework creates two separate competitive issues:

1. Generic applicants may file abbreviated new drug applications under the Hatch-Waxman pathway.
2. There is no conventional biosimilar pathway because Vumerity is not a biologic.

A generic applicant must address the listed patents and regulatory exclusivities associated with the Vumerity NDA. The product’s main commercial defense is therefore patent protection, formulation differentiation, physician adoption, and payer contracting rather than biologics exclusivity.

What patents protect Vumerity?

Vumerity is protected by a portfolio covering the active compound, pharmaceutical compositions, dosing, and methods of treating multiple sclerosis. The relevant protection is broader than a single composition-of-matter patent because the product is a prodrug with a formulation and clinical-use profile distinct from dimethyl fumarate.

Key patent categories include:

Patent category	Commercial purpose
Diroximel fumarate compound protection	Protects the active pharmaceutical ingredient or related chemical forms
Pharmaceutical composition patents	Protects dosage forms, excipients, and release characteristics
Method-of-use patents	Covers treatment of relapsing MS with diroximel fumarate
Dosing and administration claims	May cover twice-daily administration and dose-regimen details
Formulation and tolerability claims	Supports differentiation from dimethyl fumarate

The FDA Orange Book is the controlling source for patents listed against the Vumerity NDA, including patent expiry dates and any pediatric-exclusivity adjustments.[6] Patent expiry dates can differ by jurisdiction, patent family, terminal disclaimer, patent-term adjustment, patent-term extension, and the specific claim asserted against a generic applicant.

The strategic distinction is important: a generic company may be able to challenge one patent while remaining blocked by others. A formulation or method-of-use patent can delay commercial entry even when an earlier compound patent has expired.

When does Vumerity lose exclusivity?

Vumerity’s practical loss-of-exclusivity date depends on the latest enforceable patent covering the proposed generic product, not simply the date of FDA approval or the expiration of the first-listed patent.

The major exclusivity milestones are:

Milestone	Date or status
FDA approval	Oct. 30, 2019
U.S. small-molecule exclusivity	Five-year NCE exclusivity applied from approval, subject to Hatch-Waxman timing
Pediatric exclusivity	Any six-month pediatric extension depends on FDA-awarded exclusivity
Patent protection	Controlled by Orange Book-listed patents and litigation outcomes
Generic launch	Depends on Paragraph IV filings, settlement terms, court decisions, and claim scope

A five-year new chemical entity exclusivity period would ordinarily block submission of an ANDA with a Paragraph IV certification during the initial period, although patent expiry can extend the effective barrier. The relevant commercial question is when an ANDA applicant can both obtain approval and legally launch.

Which companies are challenging Vumerity patents?

Publicly disclosed generic challenges must be assessed through FDA Paragraph IV notices, Abbreviated New Drug Application litigation, and district-court dockets. The principal potential challengers are generic manufacturers with experience in dimethyl fumarate and other oral MS products.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. If the brand holder receives notice and files suit within 45 days, FDA approval of the ANDA is generally subject to a 30-month stay, unless the stay is shortened or otherwise resolved by court action.[7]

The commercial consequences are material:

• A successful challenge can produce an early generic launch.
• A failed challenge can preserve Vumerity’s branded pricing through patent expiry.
• A settlement can establish an agreed entry date, often before patent expiry.
• A covenant not to sue or claim amendment can narrow the effective protection without eliminating the patent family.

No broad biosimilar challenge applies to Vumerity. The relevant litigation risk is ANDA-based generic litigation.

What patent litigation affects Vumerity?

Vumerity litigation risk is likely to center on four questions:

1. Whether the asserted claims cover a generic diroximel fumarate product.
2. Whether the claims are valid over prior art involving fumarate chemistry and MS treatment.
3. Whether formulation claims are sufficiently specific to block a bioequivalent product.
4. Whether method-of-use claims can be enforced against a generic using a permissible skinny label.

Method-of-use patents can be difficult to enforce when a generic omits the patented indication from its labeling but the underlying product has substantial unpatented uses. The brand holder may rely on induced-infringement theories, product labeling, prescribing patterns, or evidence that the generic’s commercial conduct encourages the patented use.

For investors, the existence of an Orange Book listing is not equivalent to a guaranteed commercial barrier. Claim breadth, prior-art quality, litigation timing, and the design of the proposed generic product determine the actual risk.

What licensing deals support Vumerity?

Biogen licensed the compound that became Vumerity from Alkermes. The agreement covered development and commercialization rights for ALKS 8700, the development code for diroximel fumarate. Alkermes received financial consideration tied to licensing, development, regulatory, and commercial milestones, along with royalty economics.[8]

The license affects Vumerity’s margin structure. Product revenue does not equal retained revenue because royalties and other contractual obligations reduce the economic value to Biogen. The deal also gives Alkermes continuing exposure to Vumerity’s commercial performance without bearing the full cost of global commercialization.

How strong is the Vumerity patent estate?

Vumerity has a stronger commercial position than a product protected only by a basic compound patent because its portfolio includes formulation and use-based protection. Its patent estate is still exposed to several weaknesses.

Strengths

• Biogen owns a differentiated product rather than a reformulated version of dimethyl fumarate alone.
• The product has a clear formulation rationale tied to gastrointestinal tolerability.
• Orange Book-listed patents can trigger statutory litigation stays.
• A broad existing Tecfidera prescriber base supports branded switching.

Weaknesses

• Fumarate chemistry and MS treatment have extensive prior art.
• Generic companies can target separate patents sequentially.
• Method-of-use claims may be vulnerable to skinny-label strategies.
• Payers may force generic dimethyl fumarate before Vumerity approval.
• The product’s active metabolite is shared with Tecfidera, reducing perceived clinical differentiation for some prescribers.

Overall, Vumerity has a commercially useful but contestable patent estate. Its market protection depends on the surviving scope of formulation and use claims, not on brand recognition alone.

What generic entry risks exist for Vumerity?

The leading generic-entry scenarios are:

Scenario	Market effect
No challenge until late patent life	Vumerity retains branded share and pricing
Paragraph IV settlement with delayed entry	Moderate erosion before full generic competition
Successful early invalidity or non-infringement ruling	Rapid price and volume decline
At-risk launch	Immediate litigation and potential damages or injunction
Narrow-label generic	Initial erosion in unpatented uses, followed by broader substitution pressure

Vumerity faces a lower immediate substitution risk than Tecfidera because its formulation is different. A generic dimethyl fumarate product is not automatically a generic Vumerity product. The greater threat is economic: payers can use cheap dimethyl fumarate to pressure Vumerity pricing and restrict access even without direct pharmaceutical equivalence.

How does Vumerity affect Biogen’s revenue exposure?

Vumerity is strategically valuable because it replaces part of the revenue lost from Tecfidera. The substitution is economically imperfect:

• Tecfidera generated far higher peak revenue.
• Vumerity has a smaller eligible and willing-to-switch population.
• Vumerity requires premium reimbursement to preserve margin.
• Generic dimethyl fumarate limits the pricing ceiling.
• Biogen must fund patient support, specialty-pharmacy distribution, and licensing royalties.

Vumerity’s growth can therefore stabilize Biogen’s MS franchise without restoring the prior Tecfidera revenue peak. Its financial trajectory is more likely to mature into a mid-sized specialty product than become a replacement blockbuster on the scale of pre-generic Tecfidera.

What is the competitive outlook for Vumerity?

The MS market is moving toward high-efficacy therapies, including anti-CD20 antibodies and other agents with strong relapse and disability-control profiles. This trend limits the long-term expansion potential of oral fumarates in newly diagnosed patients with aggressive disease.

Vumerity remains relevant in several segments:

• Patients seeking an oral therapy with a familiar safety profile.
• Tecfidera patients with gastrointestinal intolerance.
• Patients and physicians preferring a non-injectable, non-infusion treatment.
• Lower-risk relapsing MS patients for whom escalation therapy is not immediately selected.
• Patients facing access or administration barriers to infusion products.

Biogen’s main commercial task is to defend Vumerity as a differentiated branded fumarate while preventing patients from leaving the franchise entirely.

Key Takeaways

• Vumerity is Biogen’s branded successor product to Tecfidera in the oral fumarate segment.
• Revenue has grown from a launch-stage base to approximately $400 million or more annually by the 2023 period.
• Growth is driven mainly by Tecfidera conversion, gastrointestinal tolerability, and Biogen’s MS commercial infrastructure.
• Generic dimethyl fumarate is the main economic competitor, even though it is not automatically a generic substitute for Vumerity.
• Vumerity is protected by compound, formulation, dosing, and method-of-use patent categories.
• FDA Orange Book listings and Paragraph IV litigation determine the practical loss-of-exclusivity timeline.
• The product has no biosimilar risk because it is a small-molecule drug.
• Vumerity can offset part of Tecfidera’s erosion but is unlikely to reproduce Tecfidera’s pre-generic revenue scale.
• Long-term pressure will come from both generic fumarates and higher-efficacy MS therapies.
• The strongest commercial defense is the combination of tolerability differentiation, payer access, patient persistence, and enforceable formulation claims.

FAQs About Vumerity’s Market and Patent Outlook

Is Vumerity a generic version of Tecfidera?

No. Vumerity contains diroximel fumarate, while Tecfidera contains dimethyl fumarate. Both generate monomethyl fumarate, but they are separate approved products with different formulations and regulatory records.

Does Vumerity have orphan-drug exclusivity?

No. Vumerity is approved for relapsing forms of MS and does not rely on orphan-drug exclusivity as its principal U.S. market protection.

Can a pharmacy automatically substitute generic dimethyl fumarate for Vumerity?

Automatic substitution depends on state law, product equivalence, payer policy, and the specific prescription. Generic dimethyl fumarate is not automatically the same product as Vumerity.

What would happen to Vumerity revenue after an early generic launch?

Revenue would likely decline through lower net pricing, formulary restrictions, and patient switching. The rate of decline would depend on the number of entrants, the scope of their labeling, and whether the generic is therapeutically or only economically substitutable.

Is Biogen’s Vumerity license from Alkermes financially significant?

Yes. The license creates royalty and other contractual obligations for Biogen while giving Alkermes continuing economic participation in Vumerity sales. Those obligations reduce Biogen’s retained product economics relative to gross revenue.

References

1. Biogen Inc. (2022). 2021 annual report. Biogen Inc.
2. Biogen Inc. (2023). 2022 annual report. Biogen Inc.
3. Biogen Inc. (2024). 2023 annual report. Biogen Inc.
4. Biogen Inc. (2019). Vumerity prescribing information. U.S. Food and Drug Administration.
5. U.S. Food and Drug Administration. (2019). FDA approves new treatment for multiple sclerosis.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
7. U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards and Paragraph IV certifications.
8. Alkermes plc. (2023). Annual report. Alkermes plc.

DrugChatter Q&A for VUMERITY

Vumerity generic name?